IP Library Granted Patent US 9,757,061
Granted Patent B2
US 9,757,061 · App. 14/842,276 · Granted Sep 12, 2017

Low oxygen in vivo analyte sensor

Inventors: Mark Shults (Madison, WI); Rathbun K. Rhodes (Madison, WI); Stuart J. Updike (Madison, WI); James H. Brauker (Addison, MI)
Assignee: DexCom, Inc.
A61B5/14865A61B5/14532
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,757,061
App. No.
14/842,276
Granted
Sep 12, 2017
Kind
B2
Abstract

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous and subcutaneous measurement of glucose in a host.

Claims (10)

1. A transcutaneous continuous sensor device for measuring a concentration of glucose in a biological fluid of a host, the device comprising:

a glucose sensor comprising an electrode and a membrane comprising a first domain and a second domain, wherein the first domain comprises an enzyme configured to react with glucose, wherein the second domain comprises polyurethaneurea;

wherein the glucose sensor is configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.6 mg/L.

2. The device of claim 1 , wherein the glucose sensor is further configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.4 mg/L.

3. The device of claim 1 , wherein the glucose sensor is further configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.15 mg/L.

4. The device of claim 1 , wherein the glucose sensor is further configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.1 mg/L.

5. The device of claim 1 , wherein the glucose sensor is further configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.05 mg/L.

6. The device of claim 1 , wherein the glucose sensor is further configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.02 mg/L.

7. The device of claim 1 , wherein the device is configured to have an operable life implanted within a host of at least about one week.

8. The device of claim 1 , further comprising sensor electronics operably connected to the electrode, wherein the sensor electronics is configured to measure a current produced by the electrode.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2015
From: SHULTS, MARK; RHODES, RATHBUN K.; UPDIKE, STUART J.; BRAUKER, JAMES H.
To: DEXCOM, INC.
Reel/Frame 036480/0101 →
Continuity (3)
Continuation 13031063 · Feb 18, 2011
Continuation 11333837 · Jan 17, 2006
Related Publication 20150374270A1 · Dec 31, 2015